alexa Lack of AMACR Immunostaining is an Independent Predictor of Poor Prognosis in Colorectal Carcinoma | OMICS International| Abstract
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
  • Research Article   
  • J Clin Exp Pathol 2016, Vol 6(1): 279
  • DOI: 10.4172/2161-0681.1000279

Lack of AMACR Immunostaining is an Independent Predictor of Poor Prognosis in Colorectal Carcinoma

Emam E1,2, Gomaa W1,3, Al-Ahwal M4,5, Mushref R6, Al-Maghrabi B6, Buhmeida A7, Al-Qahtani M7 and Jaudah Al-Maghrabi1,4*
1Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
2Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3Department of Pathology, Faculty of Medicine, Minia University, Al Minia, Egypt
4Scientific Chair for Colorectal Cancer, King Abdulaziz University, Jeddah, Saudi Arabia
5Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
6Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
7Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
*Corresponding Author : Jaudah Al-Maghrabi, Department of Pathology, Faculty of Medicine, King Abdulaziz University, P.O. BOX 80205, Jeddah 21589, Kingdom of Saudi Arabia, Tel: 00-966-12-6401000, 00-966-504680456, Fax: 00-966-12-6408433, Email: [email protected]

Received Date: May 24, 2016 / Accepted Date: Jun 16, 2016 / Published Date: Jun 17, 2016

Abstract

Background: AMACR (Alfa-Methylacyl-CoA Racemase) overexpression has become a useful biomarker of prostate cancer. In the present cohort we are aiming to analyse AMACR immunostaining in normal colonic mucosa, colorectal adenoma, and colorectal carcinoma (CRC) to explore the significance of immune-staining in relation to clinic-pathological features, prognosis, and survival.
Materials and Methods: The study included 38 normal colonic mucosae, 40 colorectal adenomas, 196 CRC, and 49 associated lymph node metastasis. Tissue microarrays were designed and constructed and immunostaining was done using anti-AMACR antibody. Results: AMACR was absent in normal colonic mucosa while it showed positive immunostaining in 47.5% of adenomas, 53.6% colorectal carcinomas and 36.7% of nodal metastasis. There was no statistically significant difference between AMACR immunostaining in primary CRC in relation adenomas, and nodal metastasis. Low AMACR immunostaining showed significant association with the occurrence nodal metastasis (p=0.039) and distant metastasis (p=0.022). There was no significant association between AMACR immune-staining and other clinic pathological parameters. Regression analysis revealed that reduced AMACR immunostaining was an independent predictor of positive surgical resection margins, presence of Lymph vascular invasion, distant metastasis, and lymph node metastasis. AMACR immunostaining was not related to both diseases free survival and overall survival. Conclusion: AMACR immune-staining correlated with nodal metastasis and distant metastasis. Loss of immunostaining of AMACR is an independent predictor of lymph vascular invasion, positive surgical margin, nodal and distant metastasis. AMACR may serve as biomarker of progression and prognosis of CRC.

Keywords: AMACR; Immunohistochemistry; Colorectal carcinoma; Prognosis

Citation: Emam E, Gomaa W, Al-Ahwal M, Mushref R, Al-Maghrabi B, et al. (2016) Lack of AMACR Immunostaining is an Independent Predictor of Poor Prognosis in Colorectal Carcinoma. J Clin Exp Pathol 6:279. Doi: 10.4172/2161-0681.1000279

Copyright: © Maghrabi JA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 10554
  • [From(publication date): 6-2016 - Nov 21, 2019]
  • Breakdown by view type
  • HTML page views: 10420
  • PDF downloads: 134
Top